NASDAQ:NVCT Nuvectis Pharma Q2 2026 Earnings Results & Report $20.29 +1.09 (+5.68%) Closing price 04:00 PM EasternExtended Trading$20.88 +0.59 (+2.91%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Nuvectis Pharma missed analyst earnings expectations in its Q2 2026 results, released August 4, 2026. The company reported EPS of -$0.30 versus the -$0.2620 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 4, 2026TimeBefore Market OpensConference Call8:30 AM ET Nuvectis Pharma EPS ResultsActual EPS-$0.30Consensus EPS -$0.2620Beat/MissMissed by -$0.0380One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersNuvectis Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Nuvectis Pharma Q2 2026 Earnings FAQ Did Nuvectis Pharma beat earnings estimates for Q2 2026? Nuvectis Pharma (NASDAQ:NVCT) reported earnings of -$0.30 per share for Q2 2026, missing the consensus estimate of -$0.2620. The report was announced on Tuesday, August 4, 2026. Nuvectis Pharma Earnings HeadlinesNuvectis Pharma (NASDAQ:NVCT) Stock Jumps 12.5% - Here's WhyNovember 8, 2026 | americanbankingnews.comFY2026 EPS Estimate for Nuvectis Pharma Decreased by AnalystNovember 8, 2026 | americanbankingnews.comA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.November 18 at 1:00 AM | Concord Gold Capital (Ad)Nuvectis Pharma IncNovember 5, 2026 | 247wallst.comNuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call TranscriptNovember 4, 2026 | seekingalpha.comNuvectis (NVCT) Q3 2026 Earnings Call TranscriptNovember 4, 2026 | finance.yahoo.comSee More Nuvectis Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvectis Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvectis Pharma and other key companies, straight to your email. Email Address About Nuvectis PharmaNuvectis Pharma (NASDAQ:NVCT) is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with serious diseases, particularly cancer. Its research and development programs target molecular pathways that may be relevant to specific tumor types. The company’s pipeline includes NXP800, an investigational small-molecule drug designed to inhibit the heat shock factor 1 pathway, and NXP900, an investigational inhibitor of the SRC and YES1 kinases. Nuvectis has studied NXP800 in ovarian cancer and is developing NXP900 for solid tumors; both remain investigational and are not approved medicines. Founded in 2020, Nuvectis is headquartered in Fort Lee, New Jersey. The company is led by co-founder, President and Chief Executive Officer Ron Bentsur.View Nuvectis Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.